ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ifinatamab deruxtecan

Also written as “Ifinatamab deruxtecan”, “I-DXd” and “Ifinatamab Deruxtecan”.

In Merck’s pipeline, Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoi. Its studies are mostly in Small Cell Lung Carcinoma · Esophageal Squamous Cell Carcinoma · Carcinoma, Non-Small-Cell Lung · Neoplasms · Lung Neoplasms, led by 2 companies.

Drug pageIfinatamab deruxtecan: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 7, 202516 company-led studies, 16 open or runningCo-development: Daiichi Sankyo and Merck, Oct 2023Next primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only1010 open or runningphase 3since Apr 7, 2025Nov 14, 2019Jun 12, 2027phase 2 · NCT07405151
Daiichi Sankyo66 open or runningphase 3since Jan 2, 2024Oct 17, 2019Apr 30, 2027phase 2 · NCT04145622
  • Named in Merck’s own pipeline as ifinatamab deruxtecan (MK-2400), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2019First study: phase 2 study in NeoplasmsFirst studyNCT04145622 · 247 enrolled · United States, Japan
  2. Jan 25, 2022Named ifinatamab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 126
  3. Feb 23, 2022Phase 2 study in Small Cell Lung CarcinomaNCT05280470 · 187 enrolled · United States, China, France and more
  4. Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
  5. Jan 2, 2024Phase 2 study in Extensive Stage-small Cell Lung CancerNCT06362252 · 123 planned · United States, France, Japan and more
  6. Jan 2, 2024Phase 3 study in Small Cell Lung CarcinomaNCT06203210 · 540 planned · United States, Australia, Austria and more
  7. Mar 19, 2024Phase 2 study in RecurrenceNCT06330064 · 680 planned · United States, Argentina, Australia and more
  8. Oct 10, 2024Phase 3 study in Esophageal Squamous Cell CarcinomaNCT06644781 · 510 planned · United States, Belgium, China and more
  9. Oct 1, 2026Primary completion moved from 2026-09-30 to 2027-07-20Date moved laterphase 2 · +10 months · NCT06362252

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in NeoplasmsNCT04145622
  2. Jul 20, 2027Primary completion: phase 2 study in Extensive Stage-small Cell Lung CancerNCT06362252
  3. Jan 30, 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06203210
  4. Jun 1, 2028Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaNCT06644781

TargetBeta

“Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoi”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 6 Daiichi Sankyo leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06644781Esophageal Squamous Cell Carcinoma · United States, Belgium, China and more3RecruitingJun 1, 2028510
NCT06330064Recurrence · United States, Argentina, Australia and more2RecruitingJul 25, 2028680
NCT06362252Extensive Stage-small Cell Lung Cancer · United States, France, Japan and more2RecruitingJul 20, 2027123
NCT06203210Small Cell Lung Carcinoma · United States, Australia, Austria and more3RecruitingJan 30, 2028540
NCT05280470Small Cell Lung Carcinoma · United States, China, France and more2Active, not recruitingMar 3, 2025187
NCT04145622Neoplasms · United States, Japan2Active, not recruitingApr 30, 2027247

How it is read

Names in the registry

  • “Ifinatamab deruxtecan”, 5 entries
  • “I-DXd”, 3 entries
  • “Ifinatamab Deruxtecan”, 3 entries
  • “Ifinatamab Deruxtecan (I-DXd)”, 3 entries
  • “I-DXD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.